Navidea Biopharmaceuticals, Inc. Navidea Biopharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Frequently Asked Questions
    • Management Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Grant Funding
  • Pipeline
  • News & Media
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • In the News

Navidea Biopharmaceuticals to Announce Third Quarter 2016 Financial Results on November 3, 2016

Oct 27, 2016

Navidea Appoints Michael M. Goldberg, M.D. President and Chief Executive Officer

Sep 26, 2016

Navidea Achieves $1 Million in Lymphoseek® Commercial Milestones

Sep 22, 2016

Navidea’s Lymphoseek® Receives Positive Opinion in Europe for a New Reduced Mass Vial

Sep 16, 2016

Navidea to Present at Upcoming Investor Conferences

Sep 14, 2016

Navidea Biopharmaceuticals to Hold Investor Update Call

Sep 6, 2016

Navidea Biopharmaceuticals Enters into Letter of Intent with Cardinal Health for the Sale of Lymphoseek® in North America

Sep 6, 2016

Navidea Biopharmaceuticals Announces 2016 Annual Meeting Results

Aug 11, 2016

Navidea Executes a Term Sheet with Cerveau Technologies to Sublicense NAV4694

Aug 8, 2016

Navidea Reports Second Quarter 2016 Financial Results

Aug 4, 2016
    • 1...
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • 15
    • 16
    • ...37
    © 2021 Navidea Biopharmaceuticals, Inc. All Rights Reserved.
    Twitter linkedin Facebook
    Privacy Policy Disclaimer Sitemap